2 Soaring Stocks With More Upside Potential to Buy and Hold

Group 1: Summit Therapeutics - Summit Therapeutics has experienced significant growth due to its leading pipeline candidate, ivonescimab, which is an investigational cancer medicine licensed from Akeso Biopharma [4] - Ivonescimab has shown excellent results in a phase 3 study for non-small cell lung cancer (NSCLC) in China, where it competes against Merck's Keytruda, indicating substantial market potential [5] - The company is conducting late-stage studies in the U.S. and is expected to release key data in the coming years, which could significantly impact its stock price [6] - Ivonescimab is being tested across various cancer types, suggesting potential for multiple approvals and label expansions in the future [7] Group 2: SoFi Technologies - SoFi Technologies has seen its shares more than double over the past year, despite challenging economic conditions [9] - The company reported a 20% year-over-year revenue increase to $771.8 million in the first quarter, although net income dropped by 19% to $71.1 million, exceeding management's guidance [10] - SoFi's membership grew to a record 10.9 million, up 34% year-over-year, highlighting the trend towards digital banking among younger generations [11] - The company has the potential to increase revenue by cross-selling additional products to existing users, with an average of 1.5 products per member [12] - SoFi continues to expand its offerings, enhancing its platform's attractiveness to consumers, positioning it well for long-term success despite potential recession risks [13]